Show simple item record

dc.contributor.authorOing, Christoph
dc.contributor.authorHentrich, M
dc.contributor.authorLorch, A
dc.contributor.authorGlaser, D
dc.contributor.authorRumpold, H
dc.contributor.authorOchsenreither, S
dc.contributor.authorRichter, S
dc.contributor.authorDieing, A
dc.contributor.authorZsch–abitz, S
dc.contributor.authorPereira, Ronnie R
dc.contributor.authorBokemeyer, C
dc.contributor.authorSeidel, C
dc.date.accessioned2020-01-29T15:17:50Z
dc.date.available2020-01-29T15:17:50Z
dc.date.issued2019en
dc.identifier.citationOing C, Hentrich M, Lorch A, Glaser D, Rumpold H, Ochsenreither S, et al. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2019:10.en
dc.identifier.pmid31838576en
dc.identifier.doi10.1007/s00432-019-03071-2en
dc.identifier.urihttp://hdl.handle.net/10541/622682
dc.description.abstractPURPOSE: Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT. METHODS: Data of multiply relapsed GCT patients receiving single-agent cabazitaxel were retrospectively analysed. Endpoints included 12-week progression-free survival (PFS) rate, disease control rate, tumour marker responses, median PFS and OS, and toxicity. RESULTS: Cabazitaxel showed limited activity in 13 heavily pre-treated GCT patients. After a median follow-up of 23 weeks (IQR 29), 69% of patients were deceased. A median of 2 cycles of cabazitaxel (range 1-7) were applied. The 12-week PFS rate was 31%. Median PFS and OS were 7 and 23 weeks, respectively. Two patients achieved objective responses (15%), three patients (23%) achieved a tumour marker decline?³?50%, and the disease control rate was 39%. Cabazitaxel was well tolerated. CTCAE¡ III-IV haemato-toxicity was most common (54%), and dose reductions were scarce (15%). CONCLUSION: In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00432-019-03071-2en
dc.titleTreatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case seriesen
dc.typeArticleen
dc.contributor.departmentHaematology and Bone Marrow Transplantation with Division of Pneumology, Department of Oncology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburgen
dc.identifier.journalJournal of Cancer Research and Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record